基于吲哚胺的儿童脑肿瘤化学免疫治疗:首次儿童Ⅰ期试验
该Ⅰ期试验评估口服IDO通路抑制剂indoximod联合替莫唑胺或放疗治疗儿童复发性脑肿瘤或新诊断弥漫性内生性桥脑胶质瘤(DIPG)的安全性与疗效。最大耐受剂量未达到,儿童剂量确定为19.2 mg/kg/次、每日两次;复发性疾病患者中位OS为13.3个月(n=68),DIPG患者为14.4个月(n=13),出现客观缓解者中位OS为25.2个月(n=26),显著长于未缓解者的7.3个月(n=37,p=0.006)。
要点
- indoximod儿童剂量为19.2 mg/kg/次、每日两次,最大耐受剂量未达到。
- 复发性疾病中位OS为13.3个月(n=68),DIPG为14.4个月(n=13)。
- 出现客观缓解者中位OS为25.2个月(n=26),显著长于未缓解者7.3个月(n=37,p=0.006)。
核心结论
- indoximod耐受良好,可安全联合化疗和放疗;初步疗效证据支持推进至Ⅱ/Ⅲ期试验。
研究设计与样本
- Ⅰ期试验(NCT02502708),纳入复发性脑肿瘤或新诊断DIPG儿童患者,共81例接受indoximod联合治疗。
- 设置两个独立剂量探索组:indoximod联合口服替莫唑胺(200 mg/m2/天×5天,28天为一周期)或联合姑息性适形放疗。
- 基线及每月采集血样进行单细胞RNA测序及配对单细胞T细胞受体测序。
主要发现
- 中位随访时间为52个月(范围39-77个月)。
- 最大耐受剂量未达到,儿童indoximod剂量确定为19.2 mg/kg/次、每日两次。
- 复发性疾病患者中位OS为13.3个月(n=68,范围0.2-62.7),DIPG患者中位OS为14.4个月(n=13,范围4.7-29.7)。
- 出现客观缓解(包括部分或混合缓解)的n=26患者中位OS为25.2个月(范围5.4-61.9),未缓解的n=37患者中位OS为7.3个月(范围0.2-62.7),p=0.006,缓解者OS超过未缓解者的3倍。
- 4例患者无活动性疾病超过36个月;单细胞测序证实出现新的循环CD8 T细胞克隆型及晚期效应表型。
关键数值与推荐
- indoximod儿童剂量为19.2 mg/kg/次、每日两次。
- 替莫唑胺剂量为200 mg/m2/天×5天,28天为一周期。
临床怎么用
- 作者认为indoximod耐受良好,可安全联合化疗和放疗。
- 作者认为初步疗效证据支持推进至Ⅱ/Ⅲ期试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, in preclinical models, inhibits anti-tumor immunity following chemotherapy. METHODS: We conducted a phase I trial (NCT02502708) of the oral IDO-pathway inhibitor indoximod in children with recurrent brain tumors or newly diagnosed diffuse intrinsic pontine glioma (DIPG). Separate dose-finding arms were performed for indoximod in combination with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles), or with palliative conformal radiation. Blood samples were collected at baseline and monthly for single-cell RNA-sequencing with paired single-cell T cell receptor sequencing. RESULTS: Eighty-one patients were treated with indoximod-based combination therapy. Median follow-up was 52 months (range 39-77 months). Maximum tolerated dose was not reached, and the pediatric dose of indoximod was determined as 19.2 mg/kg/dose, twice daily. Median overall survival was 13.3 months (n = 68, range 0.2-62.7) for all patients with recurrent disease and 14.4 months (n = 13, range 4.7-29.7) for DIPG. The subset of n = 26 patients who showed evidence of objective response (even a partial or mixed response) had over 3-fold longer median OS (25.2 months, range 5.4-61.9, p = 0.006) compared to n = 37 nonresponders (7.3 months, range 0.2-62.7). Four patients remain free of active disease longer than 36 months. Single-cell sequencing confirmed emergence of new circulating CD8 T cell clonotypes with late effector phenotype. CONCLUSIONS: Indoximod was well tolerated and could be safely combined with chemotherapy and radiation. Encouraging preliminary evidence of efficacy supports advancing to Phase II/III trials for pediatric brain tumors.
引用
- Johnson TS, MacDonald TJ, Pacholczyk R, et al. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. Neuro Oncol. 2024. PMID: 37715730. doi:10.1093/neuonc/noad174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。